Xcout IntelFulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Subscribe to see Fulcrum Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Fulcrum Therapeutics, Inc. at a glance
Fulcrum Therapeutics, Inc. is a biotech company headquartered in Cambridge, United States, founded in 2016. It is publicly listed (FULC) with a market capitalisation of $288M. Xcout tracks 28 named people at Fulcrum Therapeutics, Inc., including Alexander C. Sapir (Chief Executive Officer, President & Director). Xcout recorded 1 job posting from Fulcrum Therapeutics, Inc. in the last 90 days.
Fulcrum Therapeutics, Inc. leadership
- Alexander C. SapirChief Executive Officer, President & Director
- Alex C. SapirPresident and Chief Executive Officer, Board Member
- Alan A. MussoCFO, Treasurer & Principal Accounting Officer
- Alan MussoChief Financial Officer
- Curtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- Curtis OltmansChief Legal Officer and Head of External Affairs
22 more named people on record for Fulcrum Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Fulcrum Therapeutics, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $80M | 4 named | |
| Series A | $5M | 1 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Fulcrum Therapeutics, Inc.
Xcout recorded 1 job posting from Fulcrum Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Fulcrum Therapeutics, Inc.'s hiring signals →
Recent Fulcrum Therapeutics, Inc. news
- AcquisitionM&A registration (S-4)
- AcquisitionM&A registration (S-4)
- AcquisitionSlate Medicines and Fulcrum Therapeutics Announce Merger Agreement - citybiz
4 corporate events on record, with sources — see the full timeline →
Investors
Fulcrum Therapeutics, Inc. competitors
A few of Fulcrum Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Falcon Bio is a drug discovery company headquartered in Boston, Massachusetts, focused on targeting the root cause of cellular dysfunction to treat Friedreich's ataxia patients.
Falcon Therapeutics, Inc., in association with Skyhawk Therapeutics, conducts global clinical trials for Huntington's disease. The company serves patients with Huntington's disease by evaluating the small molecule splicing modifier SKY-0515 to lower mutant huntingtin protein levels and slow disease progression.
Foghorn Therapeutics is a biopharmaceutical company headquartered in Watertown, Massachusetts. The company is pioneering a new class of medicines that treat serious diseases by leveraging insights into the chromatin regulatory system.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Get Fulcrum Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Fulcrum Therapeutics, Inc. in Xcout Intel
- 28 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 4 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access